The investigational ADHD treatment, lisdexamfetamine dimesylate (also known as NRP104 or LDX) by Shire plc and its collaborative partner New River Pharmacuticals has yielded a good response in children with Attention Deficit Hyperactivity Disorder, it was announced today.
The data was presented at a national meeting of child and adolescent psychiatrists last weekend.
The study was done on 269 children between 6 and 12 who were treated for six months in an open label phase III study. A 60% improvement has been recorded in the primary ratings scale scores for ADHD symptoms, so the potential for LDX to be used effectively in ADHD has been recognised.
New River Pharmaceuticals formulated LDX as a new medication for ADHD which will act all day till 6 p.m.